Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23301263 | 0.90 | KCNH2 (0.43) | OPRD1KCNH2HSD11B1CNR1CNR2 | |
| SCHEMBL29943200 | 0.88 | PBRM1 (0.56) | SMARCA2SMARCA4PBRM1 | |
| SCHEMBL29943226 | 0.86 | SMARCA2 (0.54) | CKS1BSKP1SKP2OPRD1KCNH2 | |
| SCHEMBL28810427 | 0.86 | SMARCA2 (0.54) | CKS1BSKP1SKP2OPRD1KCNH2 | |
| SCHEMBL23772837 | 0.83 | CKS1B (0.47) | CKS1BSKP1SKP2DRD2PARP1 | |
| SCHEMBL29942944 | 0.82 | SMARCA2 (0.47) | OPRD1KCNH2SMARCA2SMARCA4PBRM1 | |
| SCHEMBL23301272 | 0.82 | SMARCA2 (0.47) | OPRD1KCNH2SMARCA2SMARCA4PBRM1 | |
| SCHEMBL28810458 | 0.82 | OPRD1 (0.43) | OPRD1KCNH2TSHRHSD11B1CNR1 | |
| SCHEMBL23301640 | 0.81 | OPRD1 (0.51) | OPRD1KCNH2TSHRKMT2A | |
| SCHEMBL29943255 | 0.81 | OPRD1 (0.51) | OPRD1KCNH2TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | C4 THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | SMARCC1, SMARCC2, SMARCA2 | CKS1B 612/4885SKP1 1328/4885SKP2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.